Zobrazeno 1 - 10
of 149
pro vyhledávání: '"David R Shaffer"'
Autor:
Jun Li, Stefanie Zschäbitz, Daniel P Petrylak, Margitta Retz, Prabhu Bhagavatheeswaran, Marc-Oliver Grimm, Jose Perez-Gracia, Gwenaelle Gravis, Karim Fizazi, Jeffrey C Goh, Mauricio Burotto, Daniel Castellano, Fred Saad, Andrew J Armstrong, HAKIM MAHAMMEDI, Russell K Pachynski, Louis Lacombe, Diogo Assed Bastos, Steven L McCune, Juan Carlos Vázquez Limón, Edmond M Kwan, Aude Fléchon, David R Shaffer, Neha P Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Andrea Loehr
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Background CheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 of CheckMate 9K
Externí odkaz:
https://doaj.org/article/47bed5baf90f4a54860bcc0aa14ca352
Autor:
Thomas Powles, Susheela Carroll, Marcella Fassò, Sujata Narayanan, Carol O'Hear, Sanjeev Mariathasan, Edward E. Kadel, Kobe Yuen, Indrani Sarkar, Joseph W. Kim, Michael Gordon, Jean-Pierre Delord, Paul Conkling, Lauren C. Harshman, John Powderly, Fadi Braiteh, David R. Shaffer, Yohann Loriot, Daniel P. Petrylak
Supplement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21f20f4e26dac7ce017a501823fa9fa0
https://doi.org/10.1158/1078-0432.22480052.v1
https://doi.org/10.1158/1078-0432.22480052.v1
Autor:
Thomas Powles, Susheela Carroll, Marcella Fassò, Sujata Narayanan, Carol O'Hear, Sanjeev Mariathasan, Edward E. Kadel, Kobe Yuen, Indrani Sarkar, Joseph W. Kim, Michael Gordon, Jean-Pierre Delord, Paul Conkling, Lauren C. Harshman, John Powderly, Fadi Braiteh, David R. Shaffer, Yohann Loriot, Daniel P. Petrylak
Purpose:Atezolizumab [anti–programmed death-ligand 1 (anti-PD-L1)] is well tolerated and efficacious in multiple cancers, but has not been previously evaluated in metastatic castration-resistant prostate cancer (mCRPC). This study examined the safe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13798053ba75b9ddf6160ccc2387be26
https://doi.org/10.1158/1078-0432.c.6530360.v1
https://doi.org/10.1158/1078-0432.c.6530360.v1
Autor:
Diogo Assed Bastos, Juan Carlos Vazquez Limon, Lisa G. Horvath, Héctor Manuel Sánchez López, J.N. Minatta, Daniel Castellano, Margitta Retz, Jia Li, Fred Saad, Daniel P. Petrylak, Neha P. Amin, David R. Shaffer, Arash Rezazadeh Kalebasty, Keziban Unsal-Kacmaz, Andrew J. Armstrong, Russell K. Pachynski, Karim Fizazi, Pablo González Mella
Publikováno v:
European Journal of Cancer. 160:61-71
Background Docetaxel has immunostimulatory effects that may promote an immunoresponsive prostate tumour microenvironment, providing a rationale for combination with nivolumab (programmed death-1 inhibitor) for metastatic castration-resistant prostate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72c24288e3997c05051f906f421ff817
https://doi.org/10.1016/j.ejca.2021.09.043
https://doi.org/10.1016/j.ejca.2021.09.043
Autor:
David R. Shaffer, Matthew H. Taylor, Alvaro Pinto, Daniel Heinrich, Chung-Han Lee, Chinyere E. Okpara, Øyvind Krohn Tennøe, Mehmet Asim Bilen, Donald A. Richards, Jane Wu, Randy F. Sweis, Arpit Rao, Rodolfo F. Perini, Amishi Yogesh Shah, Allen Lee Cohn, Jay Courtright, James J. Hsieh, Emmett V. Schmidt, Sara Gunnestad Ribe, Alan D. Smith, Drew W. Rasco, Robert J. Motzer, Regina Gironés Sarrió, Christopher Di Simone, Sharad Jain, Musaberk Goksel, Peter Kubiak, Nicholas J. Vogelzang
Publikováno v:
LANCET ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Summary Background Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune checkpoint inhibitors (ICIs). Pembrolizu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::560f50f96435950099b910b1a10224ee
https://doi.org/10.1016/s1470-2045(21)00241-2
https://doi.org/10.1016/s1470-2045(21)00241-2
Autor:
Yohann Loriot, Indrani Sarkar, Daniel P. Petrylak, Joseph Kim, Paul Conkling, Thomas Powles, Susheela Carroll, Lauren C. Harshman, Jean-Pierre Delord, Edward E. Kadel, Sujata Narayanan, Marcella Fassò, David R. Shaffer, Michael S. Gordon, Sanjeev Mariathasan, Kobe C. Yuen, John D. Powderly, Fadi Braiteh, Carol O'Hear
Publikováno v:
Clinical Cancer Research. 27:3360-3369
Purpose: Atezolizumab [anti–programmed death-ligand 1 (anti-PD-L1)] is well tolerated and efficacious in multiple cancers, but has not been previously evaluated in metastatic castration-resistant prostate cancer (mCRPC). This study examined the saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b757ced3c50bf4b9b4bcbdfed61b8205
https://doi.org/10.1158/1078-0432.ccr-20-1981
https://doi.org/10.1158/1078-0432.ccr-20-1981
Autor:
Karim Fizazi, Margitta Retz, Daniel P Petrylak, Jeffrey C Goh, Jose Perez-Gracia, Louis Lacombe, Stefanie Zschäbitz, Mauricio Burotto, Hakim Mahammedi, Gwenaelle Gravis, Diogo Assed Bastos, Steven L McCune, Juan Carlos Vázquez Limón, Edmond M Kwan, Daniel Castellano, Aude Fléchon, Fred Saad, Marc-Oliver Grimm, David R Shaffer, Andrew J Armstrong, Prabhu Bhagavatheeswaran, Neha P Amin, Keziban Ünsal-Kaçmaz, Xuya Wang, Jun Li, Andrea Loehr, Russell K Pachynski
BackgroundCheckMate 9KD (NCT03338790) is a non-randomized, multicohort, phase 2 trial of nivolumab plus other anticancer treatments for metastatic castration-resistant prostate cancer (mCRPC). We report results from cohorts A1 and A2 of CheckMate 9KD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27325922e5707494b2e3d966c97e1212
https://mediatum.ub.tum.de/1686755
https://mediatum.ub.tum.de/1686755
Autor:
David R. Shaffer, Gail M. Williamson
Publikováno v:
Loss and Trauma ISBN: 9781315783345
Loss and Trauma
Loss and Trauma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::351d792d488bdeaddcc9ae4a6cbf287e
https://doi.org/10.4324/9781315783345-22
https://doi.org/10.4324/9781315783345-22
Autor:
Matthew R. Zibelman, Michael Anthony Carducci, Yasser Ged, Ana M. Molina, Rahul Ravilla, David R. Shaffer, Courtney Lambert, Mahvish Tafseer, Rachel Basiura, Danielle Weismann, Rutika Kokate, Karthik Devarajan, Karen Ruth, R. Katherine Alpaugh, Fern Anari, Pooja Ghatalia, Daniel M. Geynisman, Elizabeth R. Plimack
Publikováno v:
Journal of Clinical Oncology. 40:291-291
291 Background: Combination systemic therapy with tyrosine kinase inhibitors (TKIs) and an immune checkpoint inhibitor (IO) are an established standard of care for patients with metastatic renal cell carcinoma (mRCC). We performed a phase I/II study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a76b1dcf269f9b8d7010e5ec02630fd5
https://doi.org/10.1200/jco.2022.40.6_suppl.291
https://doi.org/10.1200/jco.2022.40.6_suppl.291
Publikováno v:
Case Reports in Nephrology and Dialysis
A 30-year-old man with severe antenatal Bartter syndrome, diagnosed and treated in infancy, developed testicular carcinoma. Despite the known renal complications of cisplatin, this drug was used for his chemotherapy because of its superior antineopla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c39cfbeee8e1b9983130a4bd32e5c91
https://doi.org/10.1159/000475838
https://doi.org/10.1159/000475838